Rocket Pharmaceuticals completes $178.1 million offering

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a biotechnology company specializing in pharmaceutical preparations with a market capitalization of $1.14 billion, announced on Monday the closing of a significant public stock offering, generating net proceeds of approximately $178.1 million.

According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 6.05, though it has been quickly burning through cash. The transaction involved the sale of 13,200,000 shares of common stock at a public offering price of $12.50 per share, with underwriters fully exercising their option to purchase an additional 1,980,000 shares.

The underwriting syndicate, led by Morgan Stanley (NYSE:MS) & Co. LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co., purchased the shares at a discounted price of $11.75 per share. The offering was made under Rocket Pharmaceuticals' existing shelf registration statement, which was declared effective by the Securities and Exchange Commission (SEC) on August 16, 2024.

In conjunction with the public offering, the company also conducted a private placement of pre-funded warrants to RTW Innovation Master Fund, Ltd., resulting in additional proceeds of approximately $4.7 million. The pre-funded warrants allow the holder to purchase common stock at a nominal exercise price.

The proceeds from both the public offering and private placement are earmarked for pipeline development, commercialization preparedness and execution, and other general corporate purposes. This capital raise comes at a critical time, with the stock trading near its 52-week low after declining over 55% year-to-date.

Despite this performance, analysts maintain a Strong Buy consensus on the stock, according to InvestingPro analysis. To facilitate the offering, the company's executives, directors, and certain shareholders agreed to a 45-day lock-up period, restricting the sale of additional stock.

In other recent news, Rocket Pharmaceuticals, a biotechnology firm, has announced significant developments in its financial and clinical operations. The company has set a public offering price for 13,200,000 shares of its common stock at $12.50 per share, anticipating gross proceeds of $165 million. The offering is expected to close on December 12, 2024, and is managed by Morgan Stanley, Leerink Partners, and Cantor.

Furthermore, Rocket Pharmaceuticals reported promising long-term results from its Phase 1 study of RP-A501 for Danon disease. The study demonstrated sustained improvements in cardiac health and life quality in all evaluated patients. The firm has also completed patient enrollment for its pivotal Phase 2 trial of this therapy.

In addition, Rocket Pharmaceuticals has initiated a rolling Biologics License Application with the U.S. Food and Drug Administration for RP-L102, a potential treatment for Fanconi Anemia. Canaccord Genuity and Morgan Stanley have maintained their positive outlook on the company, reiterating a Buy rating and an Overweight rating respectively.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.